Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Relay Therapeutics, Inc.’s RLAY share price has surged by 5.63%, which has investors questioning if this is right time to sell.

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer ...

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive ...

Zai Lab's repotrectinib label expansion accepted in China for treating advanced solid tumors with NTRK gene fusion.

Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

Zai Lab Limited (NASDAQ: ZLAB) shares barely moved Monday, on word China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

An estimated 18,000 people in the United States annually suffer from new injuries to their spinal cords. Unfortunately for ...

Bayer’s Vitrakvi (larotrectinib) has been granted traditional approval by the US Food and Drug Administration (FDA) to treat ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has accepted the supplemental new drug application for ...